We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+15.9%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.81B
AUM Growth
+$276M
Cap. Flow
-$211M
Cap. Flow %
-4.39%
Top 10 Hldgs %
49.94%
Holding
159
New
17
Increased
40
Reduced
75
Closed
11

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$87M
2
RVMD icon
Revolution Medicines
RVMD
+$38.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.8M
4
AKRO
Akero Therapeutics
AKRO
+$19.6M
5
IMCR icon
Immunocore
IMCR
+$12.1M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$93.6M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$78.5M
3
BPMC
Blueprint Medicines
BPMC
+$36.5M
4
MRNA icon
Moderna
MRNA
+$34.3M
5
SYK icon
Stryker
SYK
+$32.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Technology 0.03%
3 Consumer Discretionary 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WAY
76
Waystar Holding Corp
WAY
$4.22B
$4.93M 0.1%
129,913
-20,697
-14% -$767K
GKOS icon
77
Glaukos
GKOS
$9.12B
$4.56M 0.09%
55,926
– –
SIBN icon
78
SI-BONE Inc
SIBN
$762M
$4.4M 0.09%
298,857
-241,255
-45% -$3.94M
INSP icon
79
Inspire Medical Systems
INSP
$1.48B
$4.35M 0.09%
58,648
-17,012
-22% -$1.72M
LH icon
80
Labcorp
LH
$23.1B
$4.32M 0.09%
15,065
-21,627
-59% -$5.79M
ICLR icon
81
Icon
ICLR
$12.8B
$4.24M 0.09%
+24,247
New +$4.06M
AMGN icon
82
Amgen
AMGN
$198B
$4.23M 0.09%
14,988
-9,120
-38% -$2.64M
CVS icon
83
CVS Health
CVS
$138B
$3.86M 0.08%
51,199
+21,103
+70% +$1.45M
TXG icon
84
10x Genomics
TXG
$5.4B
$3.67M 0.08%
313,836
-12,915
-4% -$168K
BNTX icon
85
BioNTech
BNTX
$23.4B
$3.35M 0.07%
33,955
-1,084
-3% -$116K
KMTS
86
Kestra Medical Technologies
KMTS
$1.38B
$3.06M 0.06%
128,711
-5,050
-4% -$90.3K
INSM icon
87
Insmed
INSM
$23.4B
$2.92M 0.06%
20,251
-61,146
-75% -$7.49M
MRK icon
88
Merck
MRK
$313B
$2.92M 0.06%
34,739
+6,500
+23% +$535K
NEO icon
89
NeoGenomics
NEO
$1.85B
$2.86M 0.06%
370,198
-542,884
-59% -$3.8M
LEGN icon
90
Legend Biotech
LEGN
$4.44B
$2.77M 0.06%
84,976
-462
-0.5% -$17.1K
AZN icon
91
AstraZeneca
AZN
$260B
$2.73M 0.06%
17,822
-1,378
-7% -$209K
CAH icon
92
Cardinal Health
CAH
$53.2B
$2.55M 0.05%
16,268
-3,744
-19% -$578K
ADPT icon
93
Adaptive Biotechnologies
ADPT
$3.49B
$2.52M 0.05%
+168,476
New +$2.05M
ILMN icon
94
Illumina
ILMN
$27.9B
$2.26M 0.05%
23,797
-3,827
-14% -$380K
BMY icon
95
Bristol-Myers Squibb
BMY
$125B
$2.15M 0.04%
47,613
+10,436
+28% +$487K
SPY icon
96
State Street SPDR S&P 500 ETF Trust
SPY
$784B
$2.07M 0.04%
3,100
– –
VKTX icon
97
Viking Therapeutics
VKTX
$4.31B
$2M 0.04%
+76,082
New +$2.27M
BAX icon
98
Baxter International
BAX
$11.4B
$1.55M 0.03%
68,084
-84,207
-55% -$2.14M
COR icon
99
Cencora
COR
$59.3B
$1.52M 0.03%
4,850
-3,120
-39% -$918K
GDX icon
100
VanEck Gold Miners ETF
GDX
$21.7B
$1.41M 0.03%
18,500
-7,700
-29% -$464K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2025 Portfolio in Review

As of Q3 2025, Bellevue Group held 159 positions worth $4.81B, up 6.1% from $4.54B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group withdrew a net $211M in Q3 2025, closing 11 positions and reducing 75 holdings. Its most notable exit was Blueprint Medicines, an estimated $36.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Avidity Biosciences worth $93.8M.

  • Bellevue Group's largest Q3 2025 buy was Avidity Biosciences: 2,152,862 shares worth $93.8M.
  • Bellevue Group added most to Revolution Medicines in Q3 2025, an estimated $38.9M increase.
  • Bellevue Group's biggest Q3 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $93.6M.
  • Bellevue Group fully exited Blueprint Medicines in Q3 2025, selling an estimated $36.5M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.81B portfolio in Q3 2025.
  • Bellevue Group opened 17 new positions and closed 11 in Q3 2025.
  • Bellevue Group's portfolio value rose 6.1% quarter-over-quarter to $4.81B.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.